4 UNIT ONE: THE LEGAL ENVIRONMENT OF BUSINESS
3A. Utilitarianism
Utilitarianism asks the decision maker to perform a cost/benefit analysis of the alternatives.
Smithson should evaluate the risks or chances of an investor buying a void policy compared to
the benefits gained from purchasing legitimate policies. The cost/benefit analysis also should
include whether he sells individual policies to individual investors or whether he sells a share of
a bundle of policies. If he does the former, the risks to the individual investor are greater than if
the latter. If the latter, the benefit of the legitimate policies may offset any loss from cancelled
policies.
4A. Decision process
First, Smithson must recognize that there is a problem. He should identify the stakeholders as
the investors, the sellers, his employees and the insurance companies that are at risk of being
defrauded. He should be familiar with laws related to insurance. Second, he should list his
alternatives and determine the goals for the decision. This is where Smithson really must
analyze the mission and goals of his company and brainstorm different actions. In step three,
Smithson selects his proposed decision with consultation and buy-in from the main
stakeholders. Fourth, Smithson should formalize and articulate the reasons for the decision
based on his analysis in prior steps. Finally, Smithson will need to later evaluate whether the
selected course of action met his goals.
ANSWER TO DEBATE THIS QUESTION IN THE REVIEWING FEATURE
AT THE END OF THE CHAPTER
Executives in large corporations are ultimately rewarded if their companies do
well, particularly as evidenced by rising stock prices. Consequently, should we let those
who run corporations decide what level of negative side effects of their goods or
services is “acceptable”? The first problem with this attitude is that executives and managers
(and even directors) may be looking at only short-run profits. They therefore might ignore the
long-run profitability to their company. If a drug that works well against a potential pandemic
causes severe side effects in some people, in the short run, this same drug may save many
lives and reduce human suffering. Thus profits could be great initially, with a consequent rise in
the stock price. In the longer run, though, when the news gets around that some of those who
took the drug suffered severe side effects, future sales of the drug might fall, thus reducing
profits and causing the stock to price to drop.
One now has to ask the question about who is in the best situation to decide the optimum
level of side effects of any drug or good or service sold. (It’s impossible to create drugs with
zero negative side effects.) Any government regulator will want to make sure that there are few,
if any, people who suffer from negative side effects. After all, the government regulator will look
bad if the press reports about those who reacted badly to a drug. Therefore, there is a bias
within any government regulatory apparatus against any good or service that has bad side
effects. More limits on drugs, though, that help millions just because few suffer side effects will
cost those who don’t obtain the drug—perhaps with their lives.